A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficile-Associated Diarrhea in Individuals Undergoing Hematopoietic Stem Cell Transplantation
The objective of this study is to demonstrate the efficacy and safety of fidaxomicin versus placebo for prophylaxis against Clostridium difficile- Associated Diarrhea (CDAD) in adult subjects undergoing hematopoietic stem cell transplantation (HSCT).
KeywordsCDAD, placebo, diarrhea, drug, fidaxomicin
Principal InvestigatorRandy A Brown, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.